ZIM Laboratories Ltd announces grant of Marketing Authorization for Azithromycin for Oral Suspension 200 mg/5ml (40 mg/ml) in Portugal, Europe

ZIM Laboratories Limited has announced today that INFARMED (Portugal) - The Portuguese National Authority of Medicines and Health Products has granted the Marketing Authorisation (MA) for one of ZIM's New Innovative Products (NIP) " Azithromycin for Oral Suspension 200 mg/5ml " in Portugal to ZIM's wholly owned European Subsidiary - SIA ZIM Laboratories Limited.

This is the 1st Marketing Authorisation (MA) for ZIM for its New Innovative Products (NIP) for Europe. Azithromycin Oral Suspension is differentiated in taste masked suspension dosage form which benefits patients who have difficulty in swallowing and children who have difficulty with bitter taste.

According to IQVIA, the EU market size for this product in 2022 was approx. USD 300Mn. Additionally other target markets for ZIM such as SE Asia & Oceania, Latin America and MENA have a combined market size of approx. USD 900Mn.

ZIM Laboratories Limited (the Company) is a research-driven pharmaceutical company which develops, manufactures and supplies differentiated generic products in oral solid dosage forms, across key therapeutic segments. The Company has state of the art in-house R&D capabilities to offer innovative drug delivery solutions using proprietary technology platforms with the aim of providing patient convenience and treatment adherence. ZIM Laboratories Limited is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE).

Shares of Zim Laboratories Ltd was last trading in BSE at Rs. 110.05 as compared to the previous close of Rs. 107.05. The total number of shares traded during the day was 32963 in over 751 trades.

The stock hit an intraday high of Rs. 112.10 and intraday low of 104.80. The net turnover during the day was Rs. 3613435.00.

Source : Equity Bulls

Keywords

ZimLaboratories INE518E01015 MarketingAuthorization INFARMED Potugal Azithromycin OralSuspension